DeNovo Sciences

Our mission is to develop and sell integrated platforms that accelerate cancer discoveries and the early detection of metastasis.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Plymouth, MI, USA
  • Currency USD
  • Employees 4
  • Website denovosciences.com

Company Summary

DeNovo Sciences is committed to the development and sale of an integrated platform that improves cancer research, diagnosis and treatment by capturing rare circulating tumor cells from a simple blood-draw. This technology will allow patients to avoid undergoing painful biopsies, and provide clinicians with important information regarding the selection of treatment courses and patient prognosis.

Team

  • Kalyan Handique, Ph.D.
    Chief Executive Officer

    Co-founder, CTO & Board Member of Handyab (acquired by BD for $275MM); 11+ years commercialization experience in microfluidics, molecular diagnostics and IVD; VP at BD diagnostics (2009-11).

  • Roger Newton, Ph.D.
    Business Adviser

    Currently the Founder, President and CEO of Esperion Therapeutics; 27+ years pharmaceutical and life science experience; Founder of Esperion I (acquired by Pfizer for $1.3 Billion); Co-discovered (Lipitor®) while a distinguished scientist at Warner Lambert/Parke-Davis (now Pfizer)

  • Mark Powelson, MBA
    Business Adviser (Management in waiting--Sales and Marketing)

    25 years of sales and marketing for HandyLab, Boehringer Manheim/Roche Diagnostics, Chiron Diagnostics, and Eli Lily

  • Steve Richvalsky
    Business Adviser (Management in waiting--CFO)

    25 years of CFO for BD Ann Arbor, HandyLab, Genomic Solutions and Ardesta

  • Ramzi Mohammad, Ph.D.
    Scientific Adviser/Collaborator

    Director, Oncology, Karmanos Cancer Institute, 30 years in cancer research

  • Kalyan Handique

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free